Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$4.55 – $5.54
Volume3,931
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.28M
Price / earnings
—
Price / book
1.52×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.41×
Profitability
Earnings per share
-$6.68
Return on assets
-206.32%
Return on equity
-218.65%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
45.95×
Quick ratio
45.95×
Cash ratio
28.17×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CURX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Revenue
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
Selling, general and administrative
$731.84K
$927.2K
$786.34K
$273.85K
Research and development
$2.59M
$2.26M
$2.31M
$677.47K
Total operating expenses
$3.33M
$3.18M
$3.09M
$951.33K
Operating income
-$3.33M
-$3.18M
-$3.09M
-$951.33K
Interest expense
$0
$0
$0
-$4.09K
Income before taxes
-$3.29M
-$3.15M
-$3.07M
-$954.06K
Income taxes
$0
$0
$0
$0
Net income
-$3.29M
-$3.15M
-$3.07M
-$954.06K
Net income attributable to common shareholders
-$3.29M
-$3.15M
-$3.07M
-$954.06K
EBITDA
-$3.33M
-$3.18M
-$3.09M
-$951.33K
Basic earnings per share
-$2.40
-$2.20
-$2.16
-$0.80
Diluted earnings per share
-$2.40
-$2.20
-$2.16
-$0.80
Recent news
Company coverage with links to the original publishers.
The Schall Law Firm is investigating Curanex Pharmaceuticals Inc. (NASDAQ: CURX) for potential securities law violations, alleging the company issued false or misleading statements and failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.
Curanex Pharmaceuticals announced significant progress on its lead asset Phyto-N, completing a pilot-scale GMP batch and dose-range finding toxicology studies with no significant adverse findings. The company maintains its target for IND submission in Q4 2026 for ulcerative colitis treatment and plans Phase 1 clinical development in Australia. The company has sufficient funding for at least the next 12 months to support development objectives.
Curanex Pharmaceuticals completed its initial public offering by having Dominari Securities fully exercise the over-allotment option, raising an additional $2.25 million and bringing total gross proceeds to $17.25 million through the issuance of 4,312,500 shares at $4.00 per share.
Curanex Pharmaceuticals completed its initial public offering of 3,750,000 shares at $4.00 per share, raising $15 million. The company, focused on botanical drugs for inflammatory diseases, began trading on Nasdaq under ticker CURX.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.